Alterity Therapeutics presents ATH434-201 Phase 2 data

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy was presented at the 150th Annual Meeting of the American Neurological Association. A poster, entitled, “ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy,” was presented by Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Coordinating Investigator for the ATH434-201 Phase 2 study. In the study, ATH434 demonstrated clinically meaningful efficacy in modifying disease progression at both 50 and 75 mg doses as well as target engagement by reducing iron accumulation in MSA affected brain regions. Analysis of the data has also shown that the baseline differences in disease severity between the arms largely explain different response in 50 mg and 75 mg treatment groups. ATH434 was well tolerated with similar adverse event rates as placebo, and no serious adverse events were attributed to study drug. “Presenting at the ANA conference allowed us to showcase the findings from our Phase 2 double-blind study of ATH434 to leading researchers and clinicians focused on neurological diseases,” said David Stamler, CEO. “The data continue to demonstrate meaningful clinical impact, including reduced disease severity on the MSA activities of daily living scale, improvements in core symptoms, and maintained function in the outpatient setting. These results reinforce the therapeutic potential of ATH434 as a disease modifying therapy and are generating continued optimism across the medical community.”